Monoclonal
Showing 1 - 25 of 8,846
Monoclonal Gammopathy of Uncertain Significance Trial in Utrecht (Zanubrutinib Oral Product)
Not yet recruiting
- Monoclonal Gammopathy of Uncertain Significance
- Zanubrutinib Oral Product
-
Utrecht, NetherlandsUniversity Medical Center Utrecht
Jul 6, 2023
Project in First-degree Relatives of Myeloma Patient - The
Recruiting
- Multiple Myeloma
- Monoclonal Gammopathy of Undetermined Significance
- Sample of Blood
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 31, 2023
Bevacizumab Combined With PD-1 Monoclonal Antibody in
Not yet recruiting
- Colorectal Cancer
- Bevacizumab Combined With PD-1 Monoclonal Antibody
- (no location specified)
Nov 8, 2023
Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)
Not yet recruiting
- Rectal Cancer
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- (no location specified)
Aug 29, 2023
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)
Not yet recruiting
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Smoldering Multiple Myeloma (SMM)
- (no location specified)
Nov 17, 2023
Quality of Life in Asymptomatic Monoclonal Gammopathies
Recruiting
- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Plasma Cell Myeloma
- Quality-of-Life Assessment
- Questionnaire Administration
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)
Not yet recruiting
- Antibody-mediated Rejection
- Kidney Tranplant
-
Hangzhou, Zhejiang, China79# Qingchun Road
Jun 21, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
Proliferative Glomerulonephritis With Monoclonal IgG Deposits Trial in Rochester (Daratumumab)
Not yet recruiting
- Proliferative Glomerulonephritis With Monoclonal IgG Deposits
-
Rochester, MinnesotaMayo Clinic Minnesota
Dec 8, 2022
Advanced Solid Tumor Trial in Bengbu (HB0030 injection)
Recruiting
- Advanced Solid Tumor
- HB0030 injection
-
Bengbu, Anhui, Chinathe First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023
Assess New Participant's Perspectives Beyond Clinical Efficacy
Not yet recruiting
- Multiple Sclerosis, Relapsing-Remitting
- (no location specified)
Nov 7, 2023
Acquired Hemophilia Trial in Tianjin (Daratumumab)
Recruiting
- Acquired Hemophilia
-
Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023
Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)
Active, not recruiting
- Atopic Dermatitis
- MG-K10/Placebo
-
Shanghai, ChinaHuashan Hospital Affiliated to Fudan University
Aug 31, 2023
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,
Completed
- HER2 Positive Breast Carcinoma
- +6 more
- Utomilumab
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Sep 22, 2022
Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)
Terminated
- Ovarian Cancer
- Monoclonal antibody hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)
Not yet recruiting
- MSS
- Rectal Cancer
- Sintilimab with Interleukin-2
- (no location specified)
Nov 1, 2023
Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),
Recruiting
- Acute Gout
- Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
- +6 more
-
Wuhan, Hubei, China
- +2 more
Oct 17, 2022
Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)
Completed
- Ovarian Cancer
- 90Y-hu3S193
- 111In-hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)
Recruiting
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
-
Najing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Sep 26, 2022
Diabetic Polyneuropathy Trial in Rochester, Aarhus, Copenhagen (Eptinezumab, Placebo)
Not yet recruiting
- Diabetic Polyneuropathy
- Eptinezumab
- Placebo
-
Rochester, Minnesota
- +2 more
Jun 30, 2023
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,
Recruiting
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Angioimmunoblastic T-cell Lymphoma
- Rituximab
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Apr 7, 2023
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance Trial in Washington (Daratumumab and
Not yet recruiting
- Peripheral Neuropathy
- Monoclonal Gammopathy of Undetermined Significance
- Daratumumab and hyaluronidase-fihj
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Sep 14, 2023
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment
Recruiting
- COVID-19 Convalescent Plasma Treatment
-
Strasbourg, FranceService des Maladies Infectieuses et Tropicales - CHU de Strasbo
Jun 15, 2023